Cyclosporine eye drops in lattice corneal dystrophy type 1: case report

To report a successful treatment of lattice corneal dystrophy type 1 (LCD1) using topical cyclosporine (CsA) eye drop emulsion 0.05%.

A 48-year-old female patient presented with bilateral LCD1characterized by corneal stromal lattice lines and visual symptoms. The patient was treated with topical CsA 0.05% twice daily for 3 months, followed by once daily for another 3 months.

Following treatment, the patient experienced a significant improvement in symptoms and resolution of corneal opacities in the treated eye.

This case report demonstrates the potential efficacy of topical CsA as a novel treatment option for LCD1, offering a noninvasive approach to manage symptoms and improve visual function. Further studies are needed to confirm these findings.